quizartinib
Selected indexed studies
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet, 2023) [PMID:37116523]
- Quizartinib. (, 2006) [PMID:38051808]
- Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. (J Hematol Oncol, 2024) [PMID:39538314]
_Worker-drafted node — pending editorial review._
Connections
quizartinib is a side effect of
Sources
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. (2023) pubmed
- Quizartinib. (2006) pubmed
- Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. (2024) pubmed
- Quizartinib. (2012) pubmed
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. (2019) pubmed
- Quizartinib (AC220): a promising option for acute myeloid leukemia. (2019) pubmed
- FLT3 inhibitor quizartinib (AC220). (2019) pubmed
- Quizartinib for the treatment of acute myeloid leukemia. (2020) pubmed
- Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial. (2025) pubmed
- Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review. (2024) pubmed